Chapter 23 Pharmacology of TMS

Publisher Summary This chapter reviews the currently available data on the pharmacology of transcranial magnetic stimulation (TMS). Only studies on healthy subjects are considered. The most often used experimental approach is to measure motor cortical excitability before (baseline) and at one or more time points after intake of a single dose of the drug under study (post measurements). The post measurements are then compared with the baseline measurements. Another experimental approach is to test drug effects in a blinded placebo-controlled parallel or crossover design. Testing the effects of central nervous system active drugs (neurotransmitters, neuromodulators) on motor cortical excitability by means of TMS has developed into an important field of research. TMS offers now a wide array of measures of motor cortical excitability that covers many different forms of excitability, such as axon and inhibitory and excitatory synaptic excitability.

[1]  H. Bostock,et al.  Two phases of intracortical inhibition revealed by transcranial magnetic threshold tracking , 2002, Experimental Brain Research.

[2]  W. Fischer,et al.  Riluzole suppresses motor cortex facilitation in correlation to its plasma level , 2000, Experimental Brain Research.

[3]  P. Schwenkreis,et al.  Influence of the N-methyl-d-aspartate antagonist memantine on human motor cortex excitability , 1999, Neuroscience Letters.

[4]  Diane Ruge,et al.  Short‐interval paired‐pulse inhibition and facilitation of human motor cortex: the dimension of stimulus intensity , 2002, The Journal of physiology.

[5]  M. Hallett,et al.  Effect of levetiracetam on human corticospinal excitability , 2001, Neurology.

[6]  C. Schönfeldt-Lecuona,et al.  Intracortical excitability is modulated by a norepinephrine-reuptake inhibitor as measured with paired-pulse transcranial magnetic stimulation , 2002, Psychopharmacology.

[7]  R. Mutani,et al.  Magnetic brain stimulation: the silent period after the motor evoked potential. , 1992, Neurology.

[8]  L. Cohen,et al.  Noradrenergic modulation of human cortex excitability by the presynaptic α2-antagonist yohimbine , 2001, Neuroscience Letters.

[9]  P. Pasqualetti,et al.  Ketamine Increases Human Motor Cortex Excitability to Transcranial Magnetic Stimulation , 2003, The Journal of physiology.

[10]  J. Liepert,et al.  Orally administered atropine enhances motor cortex excitability: a transcranial magnetic stimulation study in human subjects , 2001, Neuroscience Letters.

[11]  J C Rothwell,et al.  Short latency facilitation between pairs of threshold magnetic stimuli applied to human motor cortex. , 1996, Electroencephalography and clinical neurophysiology.

[12]  M Hallett,et al.  Dextromethorphan decreases the excitability of the human motor cortex , 1998, Neurology.

[13]  Ichiro Kanazawa,et al.  Mechanisms of intracortical I‐wave facilitation elicited with paired‐pulse magnetic stimulation in humans , 2002, The Journal of physiology.

[14]  K J Werhahn,et al.  Differential effects on motorcortical inhibition induced by blockade of GABA uptake in humans , 1999, The Journal of physiology.

[15]  U. Ziemann,et al.  Complex modulation of human motor cortex excitability by the specific serotonin re-uptake inhibitor sertraline , 2002, Neuroscience Letters.

[16]  B Conrad,et al.  Continuous intrathecal baclofen infusions induced a marked increase of the transcranially evoked silent period in a patient with generalized dystonia , 1998, Muscle & nerve.

[17]  E. Brunko,et al.  Effects of diphenylhydantoin on motor potentials evoked with magnetic stimulation. , 1994, Electroencephalography and clinical neurophysiology.

[18]  H. Heinrich,et al.  Methylphenidate and intracortical excitability: opposite effects in healthy subjects and attention‐deficit hyperactivity disorder , 2003, Acta psychiatrica Scandinavica.

[19]  M. Tegenthoff,et al.  The glutamate antagonist Riluzole suppresses intracortical facilitation , 2005, Journal of Neural Transmission.

[20]  L. Cohen,et al.  Mechanisms influencing stimulus-response properties of the human corticospinal system , 2001, Clinical Neurophysiology.

[21]  J. Rothwell,et al.  Short latency inhibition of human hand motor cortex by somatosensory input from the hand , 2000, The Journal of physiology.

[22]  C. Marsden,et al.  Corticocortical inhibition in human motor cortex. , 1993, The Journal of physiology.

[23]  A. Berardelli,et al.  Effects of diazepam, baclofen and thiopental on the silent period evoked by transcranial magnetic stimulation in humans , 1996, Experimental Brain Research.

[24]  J. Rothwell,et al.  Direct demonstration of the effect of lorazepam on the excitability of the human motor cortex , 2000, Clinical Neurophysiology.

[25]  N Accornero,et al.  Motor cortical inhibition and the dopaminergic system. Pharmacological changes in the silent period after transcranial brain stimulation in normal subjects, patients with Parkinson's disease and drug-induced parkinsonism. , 1994, Brain : a journal of neurology.

[26]  Ulf Ziemann,et al.  The α2-adrenergic agonist guanfacine reduces excitability of human motor cortex through disfacilitation and increase of inhibition , 2003, Clinical Neurophysiology.

[27]  W. Paulus,et al.  Pharmacological control of facilitatory I-wave interaction in the human motor cortex. A paired transcranial magnetic stimulation study. , 1998, Electroencephalography and clinical neurophysiology.

[28]  J. Rothwell,et al.  Muscarinic receptor blockade has differential effects on the excitability of intracortical circuits in the human motor cortex , 2000, Experimental Brain Research.

[29]  J. Rothwell,et al.  Interaction between intracortical inhibition and facilitation in human motor cortex. , 1996, The Journal of physiology.

[30]  U. Ziemann,et al.  Methylphenidate facilitates and disinhibits the motor cortex in intact humans , 2003, Neuroreport.

[31]  Janine Reis,et al.  Topiramate Selectively Decreases Intracortical Excitability in Human Motor Cortex , 2002, Epilepsia.

[32]  W. Paulus,et al.  Piracetam affects facilitatory I-wave interaction in the human motor cortex , 2001, Clinical Neurophysiology.

[33]  Walter Paulus,et al.  Demonstration of facilitatory I wave interaction in the human motor cortex by paired transcranial magnetic stimulation , 1998, The Journal of physiology.

[34]  L. Cohen,et al.  Enhancement of human cortico-motoneuronal excitability by the selective norepinephrine reuptake inhibitor reboxetine , 2002, Neuroscience Letters.

[35]  B. Steinhoff,et al.  Effects of antiepileptic drugs on motor cortex excitability in humans: A transcranial magnetic stimulation study , 1996, Annals of neurology.

[36]  Walter Paulus,et al.  Enhancement of human motor cortex inhibition by the dopamine receptor agonist pergolide: evidence from transcranial magnetic stimulation , 1996, Neuroscience Letters.

[37]  J C Rothwell,et al.  Comparison of descending volleys evoked by transcranial magnetic and electric stimulation in conscious humans. , 1998, Electroencephalography and clinical neurophysiology.

[38]  J. Rothwell,et al.  Noninvasive in vivo assessment of cholinergic cortical circuits in AD using transcranial magnetic stimulation , 2002, Neurology.

[39]  W Paulus,et al.  Changes in human motor cortex excitability induced by dopaminergic and anti-dopaminergic drugs. , 1997, Electroencephalography and clinical neurophysiology.

[40]  M Hallett,et al.  Effects of phenytoin on cortical excitability in humans , 1997, Neurology.

[41]  Walter Paulus,et al.  The effect of lorazepam on the motor cortical excitability in man , 1996, Experimental Brain Research.